Parkinson’s Research Buoyed by Alzheimer’s Advances
BioSpace
OCTOBER 1, 2023
After a groundbreaking year in the Alzheimer’s space, Parkinson’s disease researchers express renewed hope based on a greater biological understanding of neurodegeneration.
Sun.Oct 01, 2023
123 
Point-of-Care Ultrasonography in Suspected Acute Coronary Syndrome
JAMA Internal Medicine
OCTOBER 1, 2023
This case report presents the ECG findings of a patient in their 40s with post-tubercular bronchiectasis who presented with acute exacerbation of dyspnea and no chest pain.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues
BioSpace
OCTOBER 1, 2023
Eli Lilly’s Biologic License Application for its monoclonal antibody lebrikizumab was denied by the regulator after issues were found at a third-party contract manufacturing organization.
New patent expiration for King Pharms drug LEVOXYL
Drug Patent Watch
OCTOBER 1, 2023
Annual Drug Patent Expirations for LEVOXYL Levoxyl is a drug marketed by King Pharms and is included in one NDA. It is available from one supplier. There is one patent… The post New patent expiration for King Pharms drug LEVOXYL appeared first on DrugPatentWatch - Make Better Decisions.
Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought
BioSpace
OCTOBER 1, 2023
Despite a sharp downturn in initial public offering activity, New York-based gene therapy company Lexeo Therapeutics and French biotech Abivax are seeking funding for their lead candidate programs.
Which pharmaceutical companies have the most drug patents in Denmark?
Drug Patent Watch
OCTOBER 1, 2023
This chart shows the pharmaceutical companies with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
FDA Action Alert: Amgen, Alnylam and BMS
BioSpace
OCTOBER 1, 2023
The FDA will kick off October with an advisory committee meeting for Amgen’s Lumakras and target action dates for Alnylam’s patisiran and Bristol Myers Squibb’s Opdivo.
Structure Therapeutics’ Weight Loss Candidate Gets Phase I Win, Stock Soars
BioSpace
OCTOBER 1, 2023
Shares of the biotech startup jumped as much as 70% on Friday after the company reported promising early-stage results for a four-week trial that included only 24 patients.
Let's personalize your content